003060.KS
Aprogen Biologics Inc.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 1,380.00
−1.00%Year over year
Reported trailing growth
- Revenue
- +26.1%
- EBITDA
- +82.4%
- EBIT
- -88.8%
- EPS
- +58.8%
- Free cash flow
- +36.6%
- Operating cash flow
- +18.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.0%
- EBITDA
- —
- EBIT
- —
- Net income
- -62.3%
- EPS
- -3.2%
- Free cash flow
- -3.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026